ABYSS
发表于 2025-3-27 00:34:32
http://reply.papertrans.cn/16/1514/151307/151307_31.png
amygdala
发表于 2025-3-27 02:19:19
http://reply.papertrans.cn/16/1514/151307/151307_32.png
连锁
发表于 2025-3-27 08:14:57
Hematologic Malignancieshttp://image.papertrans.cn/a/image/151307.jpg
违反
发表于 2025-3-27 11:08:23
Aggressive Lymphomas978-3-030-00362-3Series ISSN 2197-9766 Series E-ISSN 2197-9774
menopause
发表于 2025-3-27 15:11:16
Reheating in Inflationary CosmologyD20 monoclonal antibody rituximab (R) to conventional chemotherapy has dramatically improved event-free survival (EFS) and overall survival (OS) in DLBCL , a significant proportion of patients are refractory or relapse following first-line treatment.
negligence
发表于 2025-3-27 19:32:17
Risks and Benefits of Mammography,lymphoma (PTCL) and as a group accounted for an estimated 24% of all lymphoid malignancies in the USA in 2016. DLBCL is the most common subtype, with an age-adjusted incidence of 6.95 cases per 100,000; is more common in whites; and has a 5-year relative survival of 59.6%. Key DLBCL risk factors inc
愤慨点吧
发表于 2025-3-28 01:29:15
http://reply.papertrans.cn/16/1514/151307/151307_37.png
交响乐
发表于 2025-3-28 02:10:43
http://reply.papertrans.cn/16/1514/151307/151307_38.png
ALIEN
发表于 2025-3-28 09:46:20
M. Castrillón-Santana,Q. C. Vuongorld Health Organization has recognized at least 29 PTCL entities, with few additional provisional entities. However, a large subset cannot be classified using current methodology and are designated as PTCL, not otherwise specified (PTCL-NOS). The molecular and genomic landscape of the major PTCL su
Headstrong
发表于 2025-3-28 11:25:12
http://reply.papertrans.cn/16/1514/151307/151307_40.png